Streptococcus pneumoniae from Palestinian Nasopharyngeal Carriers: Serotype Distribution andAntimicrobial Resistance

dc.contributor.author Nasereddin, Abedelmajeed
dc.contributor.author Shtayeh, Issa
dc.contributor.author Ramlawi, Asad
dc.contributor.author Salman, Nisreen
dc.contributor.author Salem, Ibrahim
dc.date.accessioned 2018-09-10T17:51:59Z
dc.date.available 2018-09-10T17:51:59Z
dc.date.issued 2013-12-10
dc.description.abstract Infections of Streptococcus pneumoniae in children can be prevented by vaccination; left untreated, they cause high morbidity and fatalities. This study aimed at determining the nasopharyngeal carrier rates, serotype distribution and antimicrobial resistance patterns of S. pneumoniae in healthy Palestinian children under age two prior to the full introduction of the pneumococcal 7-valent conjugate vaccine (PCV7), which was originally introduced into Palestine in a pilot trial in September, 2010. In a cross sectional study, nasopharyngeal specimens were collected from 397 healthy children from different Palestinian districts between the beginning of November 2012 to the end of January 2013. Samples were inoculated into blood agar and suspected colonies were examined by amplifying the pneumococcal-specific autolysin gene using a real-time PCR. Serotypes were identified by a PCR that incorporated different sets of specific primers. Antimicrobial susceptibility was measured by disk diffusion and MIC methods. The resulting carrier rate of Streptococcus pneumoniae was 55.7% (221/397). The main serotypes were PCV7 serotypes 19F (12.2%), 23F (9.0%), 6B (8.6%) and 14 (4%) and PCV13 serotypes 6A (13.6%) and 19A (4.1%). Notably, serotype 6A, not included in the pilot trial (PCV7) vaccine, was the most prevalent. Resistance to more than two drugs was observed for bacteria from 34.1% of the children (72/211) while 22.3% (47/211) carried bacteria were susceptible to all tested antibiotics. All the isolates were sensitive to cefotaxime and vancomycin. Any or all of these might impinge on the type and efficacy of the pneumococcal conjugate vaccines and antibiotics to be used for prevention and treatment of pneumococcal disease in the country. en_US
dc.description.sponsorship The study was funded by The Arab Company for Drug Industries & Medical Appliances, Palestine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank all the physicians, nurses, and subjects who participated in this study. Also, we thank the laboratory technical staff at the CPHL for their assistance and support. en_US
dc.identifier.citation Nasereddin A, Shtayeh I, Ramlawi A, Salman N, Salem I, et al. (2013) Streptococcus pneumoniae from Palestinian Nasopharyngeal Carriers: Serotype Distribution and Antimicrobial Resistance. PLoS ONE 8(12): e82047. doi:10.1371/journal.pone.0082047 en_US
dc.identifier.issn 1932-6203
dc.identifier.uri https://dspace.alquds.edu/handle/20.500.12213/880
dc.language.iso en_US en_US
dc.publisher Public Library of Science en_US
dc.title Streptococcus pneumoniae from Palestinian Nasopharyngeal Carriers: Serotype Distribution andAntimicrobial Resistance en_US
dc.type Article en_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RES_17_JOURNAL_paper_7.PDF
Size:
189.62 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: